<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>5(21)</volume><submitter>Floudas A</submitter><pubmed_abstract>While autoantibodies are used in the diagnosis of rheumatoid arthritis (RA), the function of B cells in the inflamed joint remains elusive. Extensive flow cytometric characterization and SPICE algorithm analyses of single-cell synovial tissue from patients with RA revealed the accumulation of switched and double-negative memory programmed death-1 receptor-expressing (PD-1-expressing) B cells at the site of inflammation. Accumulation of memory B cells was mediated by CXCR3, evident by the observed increase in CXCR3-expressing synovial B cells compared with the periphery, differential regulation by key synovial cytokines, and restricted B cell invasion demonstrated in response to CXCR3 blockade. Notably, under 3% O2 hypoxic conditions that mimic the joint microenvironment, RA B cells maintained marked expression of MMP-9, TNF, and IL-6, with PD-1+ B cells demonstrating higher expression of CXCR3, CD80, CD86, IL-1?, and GM-CSF than their PD-1- counterparts. Finally, following functional analysis and flow cell sorting of RA PD-1+ versus PD-1- B cells, we demonstrate, using RNA-Seq and emerging fluorescence lifetime imaging microscopy of cellular NAD, a significant shift in metabolism of RA PD-1+ B cells toward glycolysis, associated with an increased transcriptional signature of key cytokines and chemokines that are strongly implicated in RA pathogenesis. Our data support the targeting of pathogenic PD-1+ B cells in RA as a focused, novel therapeutic option.</pubmed_abstract><journal>JCI insight</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7710281</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint.</pubmed_title><pmcid>PMC7710281</pmcid><pubmed_authors>Marzaioli V</pubmed_authors><pubmed_authors>Moran B</pubmed_authors><pubmed_authors>Monaghan MG</pubmed_authors><pubmed_authors>Nagpal S</pubmed_authors><pubmed_authors>Krishna V</pubmed_authors><pubmed_authors>Fearon U</pubmed_authors><pubmed_authors>Low C</pubmed_authors><pubmed_authors>Floudas A</pubmed_authors><pubmed_authors>Mullan RH</pubmed_authors><pubmed_authors>Murray K</pubmed_authors><pubmed_authors>Veale DJ</pubmed_authors><pubmed_authors>Neto N</pubmed_authors><pubmed_authors>Rao N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint.</name><description>While autoantibodies are used in the diagnosis of rheumatoid arthritis (RA), the function of B cells in the inflamed joint remains elusive. Extensive flow cytometric characterization and SPICE algorithm analyses of single-cell synovial tissue from patients with RA revealed the accumulation of switched and double-negative memory programmed death-1 receptor-expressing (PD-1-expressing) B cells at the site of inflammation. Accumulation of memory B cells was mediated by CXCR3, evident by the observed increase in CXCR3-expressing synovial B cells compared with the periphery, differential regulation by key synovial cytokines, and restricted B cell invasion demonstrated in response to CXCR3 blockade. Notably, under 3% O2 hypoxic conditions that mimic the joint microenvironment, RA B cells maintained marked expression of MMP-9, TNF, and IL-6, with PD-1+ B cells demonstrating higher expression of CXCR3, CD80, CD86, IL-1?, and GM-CSF than their PD-1- counterparts. Finally, following functional analysis and flow cell sorting of RA PD-1+ versus PD-1- B cells, we demonstrate, using RNA-Seq and emerging fluorescence lifetime imaging microscopy of cellular NAD, a significant shift in metabolism of RA PD-1+ B cells toward glycolysis, associated with an increased transcriptional signature of key cytokines and chemokines that are strongly implicated in RA pathogenesis. Our data support the targeting of pathogenic PD-1+ B cells in RA as a focused, novel therapeutic option.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2021-02-20T03:05:26Z</modification><creation>2021-02-20T03:05:26Z</creation></dates><accession>S-EPMC7710281</accession><cross_references><pubmed>33148884</pubmed><doi>10.1172/jci.insight.139032</doi></cross_references></HashMap>